Sage continues downslide as Alzheimer’s study fails
In This Article:
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Recommended Reading
Alzheimer’s disease remains one of the world’s most indomitable illnesses, and on Tuesday it defeated yet another potential treatment in an experimental drug from Sage Therapeutics.
A mid-stage clinical trial has been evaluating the drug, known as dalzanemdor or SAGE-718, in patients with mild cognitive impairment or mild dementia due to Alzheimer’s. The study enrolled 174 participants and evaluated them over a 12-week treatment period. According to Sage, the drug didn’t have a significantly greater effect on cognition than a placebo.
Sage didn’t disclose any data, but said it won’t further develop the drug for Alzheimer’s based on the results. Data from a different mid-stage trial testing dalzanemdor in people with cognitive impairment associated with Huntington’s disease should come later this year, according to the company.
Alzheimer’s is an “incredibly complex and devastating condition, and people with related mild cognitive impairment and mild dementia need more treatment options,” said Barry Greene, Sage’s CEO, in a statement. “While we are disappointed by the results ... [w]e hope our work and these findings help to inform future research.”
Sage’s stock price was down more than 10% at market’s open Tuesday, but later rebounded. Shares of the Massachusetts-based biotechnology company have lost much of their value this year, and hovered just under $7 apiece Tuesday morning.
Dalzanemdor doesn’t work like the three Alzheimer’s medicines that have received approval from the Food and Drug Administration. Those therapies, along with many in development, target a misfolded protein called amyloid beta, which many researchers believe to be a root cause of the memory-robbing disease.
Instead, Sage’s drug targets the proteins on the outside of nerve cells that bind to glutamate. An essential chemical in the brain, glutamate is involved in cognition, mood regulation and memory formation. Given those functions, Sage has tested dalzanemdor across a variety of neurodegenerative diseases.
So far, though, the drug hasn’t worked. It recently failed a Parkinson’s disease study, wherein its effects on brain function were not much different than a placebo. And the now-flunked Alzheimer’s trial “removes yet another potential upside driver,” according to Paul Matteis, an analyst at the investment firm Stifel.